Ymir Genomics, MUSC to Search for Bladder Cancer Biomarkers | GenomeWeb

NEW YORK (GenomeWeb) – Ymir Genomics today announced a biomarker discovery agreement with the Medical University of South Carolina targeting bladder cancer. 

The firm aims to develop a diagnostic kit leveraging Ymir's urinary extracellular vesicle/RNA isolation technology and the expertise of the university's proteomics center. Ymir will isolate extracellular vesicles and RNA and analyze miRNA profiles of urine collected from patients with bladder cancer, as well as controls. MUSC will take the isolated vesicle preps and profile them based on proteins, glycans, and lipids. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.